ASOs are an effective treatment for disease-associated oligodendrocyte signatures in premanifest and symptomatic SCA3 mice
Molecular Therapy · 2024
DOI: 10.1016/j.ymthe.2024.02.033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2024. Verfasst von Kristen H Schuster und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Michigan, Ann Arbor, MI 48109, USA. Hauptthemen laut MEDLINE: Oligodendroglia, Machado-Joseph Disease, Oligonucleotides, Antisense, Disease Models, Animal. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, NIGMS NIH HHS, National Ataxia Foundation.
Abstract (Originalsprache)
Spinocerebellar ataxia type 3 (SCA3) is the most common dominantly inherited ataxia. Currently, no preventive or disease-modifying treatments exist for this progressive neurodegenerative disorder, although efforts using gene silencing approaches are under clinical trial investigation. The disease is caused by a CAG repeat expansion in the mutant gene, ATXN3, producing an enlarged polyglutamine tract in the mutant protein. Similar to other paradigmatic neurodegenerative diseases, studies evaluating the pathogenic mechanism focus primarily on neuronal implications. Consequently, therapeutic interventions often overlook non-neuronal contributions to disease. Our lab recently reported that oligodendrocytes display some of the earliest and most progressive dysfunction in SCA3 mice. Evidence of disease-associated oligodendrocyte signatures has also been reported in other neurodegenerative diseases, including Alzheimer's disease, amyotrophic lateral sclerosis, Parkinson's disease, and Huntington's disease. Here, we assess the effects of anti-ATXN3 antisense oligonucleotide (ASO) treatment on oligodendrocyte dysfunction in premanifest and symptomatic SCA3 mice. We report a severe, but modifiable, deficit in oligodendrocyte maturation caused by the toxic gain-of-function of mutant ATXN3 early in SCA3 disease that is transcriptionally, biochemically, and functionally rescued with anti-ATXN3 ASO. Our results highlight the promising use of an ASO therapy across neurodegenerative diseases that requires glial targeting in addition to affected neuronal populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, University of Michigan, Ann Arbor, MI 48109, USA.
- Department of Neurology, University of Michigan, Ann Arbor, MI 48109, USA; Neuroscience Graduate Program, University of Michigan, Ann Arbor, MI 48109, USA.
- Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI 48109, USA.
- Department of Neurology, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address: hayleymc@med.umich.edu.
Förderung
- NINDS NIH HHS
- NIGMS NIH HHS
- National Ataxia Foundation
- Ionis Pharmaceuticals
- NIH
Zitieren
APA
Schuster, K. H., Zalon, A. J., DiFranco, D. M., Putka, A. F., Stec, N. R., Jarrah, S. I., Naeem, A., Haque, Z., Zhang, H., Guan, Y., & McLoughlin, H. S. (2024). ASOs are an effective treatment for disease-associated oligodendrocyte signatures in premanifest and symptomatic SCA3 mice. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2024.02.033
Vancouver
Schuster KH, Zalon AJ, DiFranco DM, Putka AF, Stec NR, Jarrah SI, et al. ASOs are an effective treatment for disease-associated oligodendrocyte signatures in premanifest and symptomatic SCA3 mice. Molecular Therapy. 2024. doi:10.1016/j.ymthe.2024.02.033
BibTeX
@article{Schuster2024,
author = {Schuster, Kristen H and Zalon, Annie J and DiFranco, Danielle M and Putka, Alexandra F and Stec, Nicholas R and Jarrah, Sabrina I and Naeem, Arsal and Haque, Zaid and Zhang, Hanrui and Guan, Yuanfang and McLoughlin, Hayley S},
title = {ASOs are an effective treatment for disease-associated oligodendrocyte signatures in premanifest and symptomatic SCA3 mice},
journal = {Molecular Therapy},
year = {2024},
doi = {10.1016/j.ymthe.2024.02.033}
}
EUVIMED